Drug intelligence / Profile preview

AZD4316

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD4316 is an investigational small molecule drug that was developed by AstraZeneca as a potential treatment for respiratory syncytial virus (RSV) infection. It acts as a potent RSV fusion inhibitor, targeting the viral fusion process to prevent infection of host cells. Clinical development reached Phase 1 but was discontinued, and the compound is no longer in active development[3][4][1]. The drug was administered orally in clinical studies[1].

Other names: AZD-4316AZD4316AZD 4316

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on AZD4316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD4316.

Explore the full profile